Platform FateAI: Development of DNA methylation-based tests for early diagnosis and prognostic definition of tumor lesions from liquid biopsy.

The FateAI E Line is designed for the early identification and histological characterization of tumors through DNA methylation markers. It is a solution based on recent discoveries that involved one of the proponents: Dr. Pier Vitale Nuzzo. Immunoprecipitation of circulating free DNA (cfDNA) methylation followed by high-throughput sequencing (cfMeDIP-seq) is an innovative and highly sensitive technique that allows the non-invasive identification and classification of tumors through the identification of the tumor methylation profile in biological fluids. The identification and characterization of the cfDNA methylome through the CfMeDIP-seq assay has allowed the identification in plasma of the presence of the methylation profile of seven types of tumors (colon, pancreas, kidney, breast, lung, urothelial, and acute myeloid leukemia) with very high sensitivity and specificity, using small amounts of DNA (10ng) at a lower cost than traditional methylation analysis techniques (Shu Yi Shen, Rajat Singhania, Gordon Fehringer, Ankur Chakravarthy, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature 2018 volume 563:579–583).